Ralph Torbay

Bio:

Ralph is an experienced commercial leader with a proven track record of successful oncology launches and significant immuno-oncology experience. At Immunocore, he built the global commercial organization that successfully launched the world's first T-cell receptor (TCR) therapeutic and T-cell engager in a solid tumor, delivering $144 million in first-year sales followed by 11 quarters of consecutive growth across more than 25 countries. Ralph has a proven track record of launching first-in-class therapeutics and building sustainable commercial organizations. Prior to joining Immunocore, he was Global Head of Hematology Marketing at AstraZeneca, where he helped build their global hematology franchise and launched three major drugs in oncology, including the first checkpoint inhibitor in stage III unresectable non-small cell lung cancer. Before AstraZeneca, Ralph worked at Novartis Oncology, holding roles of increasing responsibility and working on five products in several disease areas across hematology and oncology. His experience spans several disease areas including hematology, oncology, and autoimmune diseases, as well as diverse therapeutic platforms such as immuno-oncology, CAR-T therapy, small molecules, and gene therapies, in both industry roles and as a strategic healthcare consultant.

Ralph earned his Master of Business Administration degree at the Simon Graduate School of Business, University of Rochester, and a Bachelor of Science in Biotechnology with a minor in Bioinformatics from Rochester Institute of Technology.